Purchase Order 75N91018P00381

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $17,430.36 on June 21, 2018, with an ultimate completion date of July 23, 2018. No set-aside was used. Place of performance is Bethesda, Maryland. The order covers analytical laboratory instruments or related consumables and services, consistent with Agilent's product line of gas chromatography-mass spectrometry systems, liquid chromatography-mass spectrometry equipment, and associated supplies.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $5,124.04 on May 15, 2018, with ultimate completion on June 30, 2019. No set-aside was used. Place of performance is Bethesda, Maryland. The order is firm fixed price.</p>

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $17,852.40 on August 23, 2018, with ultimate completion on August 23, 2019. The order carries fixed-price pricing with economic price adjustment and no set-aside designation. Place of performance is Bethesda, Maryland. The purchase order procures analytical laboratory instrumentation, consumables, or maintenance services typical of Agilent's federal portfolio in analytical chemistry equipment supply.

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $19,429.50 on June 11, 2018, for firm fixed price delivery completing July 6, 2018. Place of performance is Bethesda, Maryland. No set-aside was used. The order procures analytical laboratory instruments, consumables, or maintenance services consistent with Agilent's role as a supplier of gas chromatography-mass spectrometry systems, liquid chromatography-mass spectrometry equipment, and associated...

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $17,948.50 on September 19, 2019, for drugs and biologicals, with ultimate completion on October 19, 2019. Place of performance is Bethesda, Maryland. The order uses firm fixed-price pricing with no set-aside category.</p>

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $16,018.50 on January 31, 2018, with an ultimate completion date of January 25, 2019. The order carries fixed-price pricing with economic price adjustment and no set-aside designation. Place of performance is Bethesda, Maryland. The purchase order procures analytical laboratory instruments and associated consumables or services, consistent with Agilent's role as a supplier of gas chromatography-mass...

<p>The National Cancer Institute issued a purchase order to Agilent Technologies Inc. valued at $12,914.00 on July 20, 2017, with an ultimate completion date of July 19, 2018. Place of performance is San Diego, California. The order carries firm fixed price pricing with no set-aside designation. The procurement covers analytical laboratory instruments and associated consumables or services typical of Agilent's federal equipment and maintenance portfolio.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $13,570.50 on July 6, 2020, for drugs and biologicals, with completion on August 6, 2020. Work is performed at Marshtonlon, Delaware. The order carries firm fixed price terms with no set-aside designation.</p>

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for $18,781.20 on May 31, 2018, with an ultimate completion date of May 31, 2019. No set-aside was used. Performance takes place in Marshallton, Delaware. The order is for firm fixed price supply of analytical laboratory instruments and associated consumables from Agilent's Customer Service and Sales Division, a manufacturer of gas chromatography-mass spectrometry systems, liquid chromatography-mass...

<p>The National Cancer Institute issued a delivery order to Agilent Technologies Inc. on January 18, 2018, with a ceiling value of $17,428.85. The order was placed under the GSA Scientific Equipment and Services Multiple Award Schedule (FSS-66).</p> <p>Place of performance is Bethesda, MD. The order has an ultimate completion date of February 18, 2018. No set-aside was used.</p>